Abstract 113P
Background
Tumor tissue preservation methods affect proteome profiles differently. To date, no studies have reported a deep proteome comparison of four tissue preservation methods and their corresponding proteome profiles. This study sought to assess the effect of different preservation methods on quantitative proteomics of human breast adjacent normal (NC) and tumor tissues (TC) preserved in Allprotect, snap-frozen by LN2, RNAlater, and formalin solution embedded in paraffin (FFPE).
Methods
Around 7 patients’ TC and NC were preserved in four different storage conditions, which include Allprotect, LN2, RNAlater, and FFPE. A comprehensive deep proteomics analysis using mass spectrometry has been performed to evaluate the effect of storage conditions on the preservation of proteins. Protein yield and coverage were compared in four storage conditions to determine the optimum storage conditions for tissue samples to perform proteomics analysis. Unique proteins obtained from each condition were further analyzed to examine the effect of storage conditions on subcellular location. Differential analysis was performed on all individual conditions to compare the unique statistically differentially expressed proteins.
Results
TC tissues showed the highest protein yield compared to NC because the fat portion was higher in NC. The FFPE condition, followed by RNAlater, was determined to have the maximum protein coverage. Unique proteins could be detected from FFPE samples, providing a hint of the modifications induced during the paraffinization. However, the differential analysis showed more unique proteins in the Allprotect storage conditions, followed by RNAlater. The proteins CNDP2 and PLIN4 showed dysregulation in the TC sample despite the different storage conditions and may be used as therapeutic markers for breast cancer. Biological pathway analysis showed spliceosome and PPAR signaling pathways were enriched in TC compared to NC tissue.
Conclusions
This study evaluated the effects of different tissue preservation methods on proteomics analysis.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
IIT Bombay.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
114P - Circulating microRNAs and response to oncological and surgical therapy in patients with locally advanced gastric cancer
Presenter: Vasileia Kokala-Dimitropoulou
Session: Cocktail & Poster Display session
Resources:
Abstract
115P - BrainStorm-NSE: Serum neuron-specific enolase as a biomarker for central nervous system metastases: A prospective cohort study
Presenter: Diogo Martins-Branco
Session: Cocktail & Poster Display session
Resources:
Abstract
116P - Switching to a multigenic parallel sequencing approach: The landscape of biomarkers profiling changing between immunohistochemistry and next generation sequencing advantages and sustainability from a public hospital in Northern Italy
Presenter: Giulia Ghirardi
Session: Cocktail & Poster Display session
Resources:
Abstract
117P - Homologous recombination deficiency (HRD) by shallow whole genome sequencing (sWGS): Seamless integration in an existing NGS somatic oncology workflow
Presenter: Etienne Muller
Session: Cocktail & Poster Display session
Resources:
Abstract
118P - Molecular diagnostics of gastrointestinal stromal tumors in the era of precision oncology
Presenter: Alena Kalfusova
Session: Cocktail & Poster Display session
Resources:
Abstract
119P - De novo and histologically transformed small-cell lung cancer is sensitive to lurbinectedin treatment through the modulation of EMT and NOTCH signaling pathways
Presenter: Triparna Sen
Session: Cocktail & Poster Display session
Resources:
Abstract
120P - Anti-angiogenic therapy or immunotherapy? A multicenter real-world study of patients with advanced non-small cell lung cancer with EGFR / HER2 exon 20 insertion mutations
Presenter: Tianqing Chu
Session: Cocktail & Poster Display session
Resources:
Abstract
121P - Clinical outcomes of compound EGFR mutation in non-small cell lung cancer: A national, retrospective, multicenter study
Presenter: Aurélien Brindel
Session: Cocktail & Poster Display session
Resources:
Abstract
122P - Molecular testing, treatment, and response of patients with advanced solid tumors harboring an NTRK gene fusion: Second interim results of the REALTRK registry
Presenter: Sebastian Lange
Session: Cocktail & Poster Display session
Resources:
Abstract
123P - Incidence and outcomes of anaplastic lymphoma kinase (ALK) and ROS 1 positive advanced NSCLC: A real world experience
Presenter: Stalin Chowdary Bala
Session: Cocktail & Poster Display session
Resources:
Abstract